Menu
  Home
Lab members
  Research
  Publications
  Contacts




Welcome to the Genazzani lab

Welcome to the Genazzani lab. It was established in 2004 and is part of the Department of Pharmaceutical Sciences of the Università del Piemonte Orientale. The main lab is located in the "Alcoa" Building (www.novarasviluppo.it/en/the-hub/the-building/), an architectural masterpiece by Renzo Piano, while the pharmacogenetics section is now located in a purpose-built laboratory in the "Wild" Building (www.pharm.unipmn.it/), an example of urban re-conversion of industrial settings, as it used to be a cotton industry.

Historically, Armando Genazzani has focused its interests in basic mechanisms underlying calcium signalling, but in recent years a number of other research topics (for example, in the field of neuroscience and cancer biology) have also been pursued by the lab. In recent years, many lab members are devoting their efforts to the possibility that NAMPT, an enzyme involved in NAD synthesis, can be a pharmacological target in cancer. The lab is now starting to maintain a webpage on preclinical evidences that support the use of NAMPT inhibitors in cancer.

The lab also has strong ties with medicinal chemistry groups to pursue early drug discovery (www.symech.it) and with clinicians to understand individual differences in drug responses (www.farmacogeneticanovara.it).

The lab always welcomes applications from talented undergraduates, graduates and post-doctoral fellows willing to join our efforts and ideas for collaborations, including multidisciplinary approaches.


Latest publications
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014.
Marcian˛ I(1), Ingrasciotta Y(1), Giorgianni F(1), Bolcato J(2), Chinellato A(2), Pirolo R(2), Di Giorgio A(3), Manna S(3), Ientile V(1), Gini R(4), Santarpia M(5), Genazzani AA(6), Uomo I(7), Pastorello M(7), Pollina Addario SW(8), Scondotto S(8), Cananzi P(9), Da Cas R(10), Traversa G(10), Rossi M(11), Sottosanti L(12), Caputi AP(1,)(13), Trifir˛ G(14,)(15).
BioDrugs. 2016 May 2. [Epub ahead of print]
[Show abstract ]  
Pharmacological enhancement of mGlu5 receptors rescues behavioral deficits in SHANK3 knock-out mice.
Vicidomini C(1), Ponzoni L(2), Lim D(3), Schmeisser MJ(4,)(5), Reim D(4), Morello N(6), Orellana D(1), Tozzi A(7), Durante V(8), Scalmani P(9), Mantegazza M(10), Genazzani AA(3), Giustetto M(5), Sala M(1), Calabresi P(8), Boeckers TM(4), Sala C(1), Verpelli C(1).
Mol Psychiatry. 2016 Mar 29. doi: 10.1038/mp.2016.30. [Epub ahead of print]
[Show abstract ]  
Extracellular Nicotinamide Phosphoribosyltrasferase (eNAMPT), A New Cancer Metabokine.
Grolla AA(1), Travelli C(1), Genazzani AA(1), Sethi JK(1).
Br J Pharmacol. 2016 Apr 29. doi: 10.1111/bph.13505. [Epub ahead of print]
[Show abstract ]  
Ring finger protein 10 is a novel synaptonuclear messenger encoding activation of NMDA receptors in hippocampus.
Dinamarca MC(1), Guzzetti F(1), Karpova A(2), Lim D(3), Mitro N(1), Musardo S(1), Mellone M(1), Marcello E(1), Stanic J(1), Samaddar T(1), BurguiŔre A(4), Caldarelli A(3), Genazzani AA(3), Perroy J(4), Fagni L(4), Canonico PL(3), Kreutz MR(2), Gardoni F(1), Luca MD(1).
Elife. 2016 Mar 15;5. pii: e12430. doi: 10.7554/eLife.12430.
[Show abstract ]  
Common European Mitochondrial Haplogroups in the Risk for Radiation-induced Subcutaneous Fibrosis in Breast Cancer Patients.
Terrazzino S(1), Deantonio L(2), Cargnin S(1), Donis L(3), Pisani C(3), Masini L(3), Gambaro G(3), Canonico PL(1), Genazzani AA(1), Krengli M(4).
Clin Oncol (R Coll Radiol). 2016 Mar 9. pii: S0936-6555(16)00084-4. doi: 10.1016/j.clon.2016.02.007. [Epub ahead of print]
[Show abstract ]  

See complete list of pubblications

Website maintained by Dmitry Lim